
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6182572/publications.pdf Version: 2024-02-01



LIAVIED MEANA

#	Article	IF	CITATIONS
1	High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers. International Journal of Neuropsychopharmacology, 2022, 25, 468-478.	2.1	6
2	5-HT _{2A} receptor-mediated Gα _{q/11} activation in psychiatric disorders: A postmortem study. World Journal of Biological Psychiatry, 2021, 22, 505-515.	2.6	8
3	FOXP2 expression and gray matter density in the male brains of patients with schizophrenia. Brain Imaging and Behavior, 2021, 15, 1403-1411.	2.1	12
4	Spinophilin expression in postmortem prefrontal cortex of schizophrenic subjects: Effects of antipsychotic treatment. European Neuropsychopharmacology, 2021, 42, 12-21.	0.7	2
5	Adrenergic Modulation With Photochromic Ligands. Angewandte Chemie, 2021, 133, 3669-3675.	2.0	5
6	Adrenergic Modulation With Photochromic Ligands. Angewandte Chemie - International Edition, 2021, 60, 3625-3631.	13.8	29
7	5-HT2A receptor- and M1 muscarinic acetylcholine receptor-mediated activation of Gαq/11 in postmortem dorsolateral prefrontal cortex of opiate addicts. Pharmacological Reports, 2021, 73, 1155-1163.	3.3	4
8	Functional approaches to the study of G-protein-coupled receptors in postmortem brain tissue: [35S]GTPγS binding assays combined with immunoprecipitation. Pharmacological Reports, 2021, 73, 1079-1095.	3.3	2
9	Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways. Frontiers in Pharmacology, 2021, 12, 682602.	3.5	7
10	Opposite alterations of 5ÂHT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile. Translational Psychiatry, 2021, 11, 302.	4.8	8
11	Characterization of dopamine D2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia. Pharmacological Reports, 2021, 73, 1136-1146.	3.3	3
12	Special issue "role of G-proteins and GPCR-mediated signaling in the pathophysiology and treatment of psychiatric disorders― Pharmacological Reports, 2021, 73, 967-969.	3.3	0
13	α2A- and α2C-adrenoceptor expression and functionality in postmortem prefrontal cortex of schizophrenia subjects. European Neuropsychopharmacology, 2021, 52, 3-11.	0.7	7
14	Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment. Translational Psychiatry, 2021, 11, 643.	4.8	10
15	Functional coupling of M1 muscarinic acetylcholine receptor to Gαq/11 in dorsolateral prefrontal cortex from patients with psychiatric disorders: a postmortem study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 869-880.	3.2	8
16	Fundamental features of receptor-mediated Gαi/o activation in human prefrontal cortical membranes: A postmortem study. Brain Research, 2020, 1747, 147032.	2.2	0
17	Serum β-endorphin levels are associated with addiction to suicidal behavior: A pilot study. European Neuropsychopharmacology, 2020, 40, 38-51.	0.7	4
18	Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Gαi1- and neutral antagonism for Gαq/11-proteins in human brain cortex. European Neuropsychopharmacology, 2020, 36, 83-89.	0.7	22

#	Article	IF	CITATIONS
19	Calcium-binding proteins are altered in the cerebellum in schizophrenia. PLoS ONE, 2020, 15, e0230400.	2.5	16
20	Ribosomal Protein S6 Hypofunction in Postmortem Human Brain Links mTORC1-Dependent Signaling and Schizophrenia. Frontiers in Pharmacology, 2020, 11, 344.	3.5	17
21	Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression. Molecular Neurobiology, 2019, 56, 3038-3052.	4.0	12
22	Chronic fluoxetine reverses the effects of chronic corticosterone treatment on α2-adrenoceptors in the rat frontal cortex but not locus coeruleus. Neuropharmacology, 2019, 158, 107731.	4.1	4
23	Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia. Journal of Psychopharmacology, 2019, 33, 1132-1140.	4.0	21
24	Big Data Challenges Targeting Proteins in GPCR Signaling Pathways; Combining PTML-ChEMBL Models and [35S]GTPI ³ S Binding Assays. ACS Chemical Neuroscience, 2019, 10, 4476-4491.	3.5	21
25	Cartography of hevin-expressing cells in the adult brain reveals prominent expression in astrocytes and parvalbumin neurons. Brain Structure and Function, 2019, 224, 1219-1244.	2.3	20
26	CIBERSAM: Ten years of collaborative translational research in mental disorders. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 1-8.	0.3	5
27	Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins. European Neuropsychopharmacology, 2019, 29, 1453-1463.	0.7	32
28	Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics. Translational Psychiatry, 2019, 9, 306.	4.8	16
29	Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 1-8.	1.8	68
30	Optimization and pharmacological characterization of receptorâ€mediated G i/o activation in postmortem human prefrontal cortex. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 649-659.	2.5	4
31	Differential α _{2A} - and α _{2C} -adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex. Journal of Psychopharmacology, 2019, 33, 244-249.	4.0	10
32	Serotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram. Neuropharmacology, 2018, 133, 491-502.	4.1	11
33	Therapeutic Drug Monitoring of Second-Generation Antipsychotics for the Estimation of Early Drug Effect in First-Episode Psychosis: A Cross-sectional Assessment. Therapeutic Drug Monitoring, 2018, 40, 257-267.	2.0	6
34	Functional coupling between adenosine A1 receptors and G-proteins in rat and postmortem human brain membranes determined with conventional guanosine-5â€2-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding or [35S]GTPγS/immunoprecipitation assay. Purinergic Signalling, 2018, 14, 177-190.	2.2	2
35	Characterisation of spinophilin immunoreactivity in postmortem human brain homogenates. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 236-242.	4.8	4
36	Structural and Functional Characterization of the Interaction of Snapin with the Dopamine Transporter: Differential Modulation of Psychostimulant Actions. Neuropsychopharmacology, 2018, 43, 1041-1051.	5.4	7

J JAVIER MEANA

#	Article	IF	CITATIONS
37	Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders. Biochemical Pharmacology, 2018, 157, 258-265.	4.4	15
38	Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway. Neuropsychopharmacology, 2018, 43, 2028-2035.	5.4	59
39	Histamine H ₃ receptor-mediated G-protein activation in postmortem human prefrontal cortical membranes. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-132.	0.0	0
40	Chronic citalopram administration desensitizes prefrontal cortex but not somatodendritic α2-adrenoceptors in rat brain. Neuropharmacology, 2017, 114, 114-122.	4.1	7
41	Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia. Neuropharmacology, 2017, 116, 196-207.	4.1	42
42	The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia. European Neuropsychopharmacology, 2017, 27, 180-191.	0.7	20
43	Biomarcadores en PsiquiatrÃa: entre el mito y la realidad clÃnica. Revista De PsiquiatrÃa Y Salud Mental, 2017, 10, 183-184.	1.8	25
44	Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects. Nature Neuroscience, 2017, 20, 1247-1259.	14.8	79
45	A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients. Journal of Clinical Psychopharmacology, 2017, 37, 569-577.	1.4	16
46	Biomarkers in Psychiatry: Between myth and clinical reality. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2017, 10, 183-184.	0.3	1
47	Functional activation of $\hat{G}_{\pm q}$ coupled to 5-HT2A receptor and M1 muscarinic acetylcholine receptor in postmortem human cortical membranes. Journal of Neural Transmission, 2017, 124, 1123-1133.	2.8	13
48	Schizophrenia and depression, two poles of endocannabinoid system deregulation. Translational Psychiatry, 2017, 7, 1291.	4.8	38
49	Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Frontiers in Pharmacology, 2016, 7, 130.	3.5	52
50	Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex. Frontiers in Pharmacology, 2016, 7, 415.	3.5	56
51	Alpha2C-adrenoceptor Del322-325 polymorphism and risk of psychiatric disorders: significant association with opiate abuse and dependence. World Journal of Biological Psychiatry, 2016, 17, 308-315.	2.6	7
52	Effect of subchronic corticosterone administration on α2-adrenoceptor functionality in rat brain: an in vivo and in vitro study. Psychopharmacology, 2016, 233, 3861-3867.	3.1	3
53	Altered CSNK1E, FABP4 and NEFH protein levels in the dorsolateral prefrontal cortex in schizophrenia. Schizophrenia Research, 2016, 177, 88-97.	2.0	26
54	Allosteric signaling through an mGlu2 and 5-HT _{2A} heteromeric receptor complex and its potential contribution to schizophrenia. Science Signaling, 2016, 9, ra5.	3.6	91

J JAVIER MEANA

#	Article	IF	CITATIONS
55	Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. Journal of Psychiatry and Neuroscience, 2016, 41, E46-E55.	2.4	65
56	The endocannabinoid system is altered in the postâ€mortem prefrontal cortex of alcoholic subjects. Addiction Biology, 2015, 20, 773-783.	2.6	34
57	Transcription factor Sp4 regulates expression of nervous wreck 2 to control NMDAR1 levels and dendrite patterning. Developmental Neurobiology, 2015, 75, 93-108.	3.0	21
58	α ₂ -Adrenoceptor Antagonists: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of Pyridinoguanidine, Pyridino-2-aminoimidazoline and Their Derivatives. Journal of Medicinal Chemistry, 2015, 58, 963-977.	6.4	26
59	Up-regulated 14-3-3β and 14-3-3ζ proteins in prefrontal cortex of subjects with schizophrenia: effect of psychotropic treatment. Schizophrenia Research, 2015, 161, 446-451.	2.0	7
60	Adenosine A1 receptors are selectively coupled to Gαi-3 in postmortem human brain cortex: Guanosine-5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding/immunoprecipitation study. European Journal of Pharmacology, 2015, 764, 592-598.	3.5	8
61	Transcription factor SP4 phosphorylation is altered in the postmortem cerebellum of bipolar disorder and schizophrenia subjects. European Neuropsychopharmacology, 2015, 25, 1650-1660.	0.7	10
62	Semaphorin and plexin gene expression is altered in the prefrontal cortex of schizophrenia patients with and without auditory hallucinations. Psychiatry Research, 2015, 229, 850-857.	3.3	31
63	Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects. Journal of Psychopharmacology, 2015, 29, 1137-1145.	4.0	8
64	Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Design, Development and Therapy, 2014, 8, 263.	4.3	13
65	Increased α2- and β1-adrenoceptor densities in postmortem brain of subjects with depression: Differential effect of antidepressant treatment. Journal of Affective Disorders, 2014, 167, 343-350.	4.1	34
66	Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment. Neuropharmacology, 2014, 86, 311-318.	4.1	63
67	Recent cocaine use is a significant risk factor for sudden cardiovascular death in 15-49-year-old subjects: a forensic case-control study. Addiction, 2014, 109, 2071-2078.	3.3	39
68	Involvement of serotonin 5-HT3 receptors in the modulation of noradrenergic transmission by serotonin reuptake inhibitors: a microdialysis study in rat brain. Psychopharmacology, 2013, 229, 331-344.	3.1	15
69	Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects. European Neuropsychopharmacology, 2013, 23, 852-864.	0.7	71
70	Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophrenia Research, 2013, 148, 145-150.	2.0	65
71	Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: A pilot study of relationship to negative symptoms. Journal of Psychiatric Research, 2013, 47, 926-934.	3.1	39
72	Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties. Archiv Der Pharmazie, 2013, 346, 171-179.	4.1	12

#	Article	IF	CITATIONS
73	Chronic Pain Leads to Concomitant Noradrenergic Impairment and Mood Disorders. Biological Psychiatry, 2013, 73, 54-62.	1.3	149
74	Antidepressant-like properties of three new α2-adrenoceptor antagonists. Neuropharmacology, 2013, 65, 13-19.	4.1	22
75	Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: basal contents and effects of psychotropic medications. International Journal of Neuropsychopharmacology, 2013, 16, 683-689.	2.1	14
76	Identification of Three Residues Essential for 5-Hydroxytryptamine 2A-Metabotropic Glutamate 2 (5-HT2A·mGlu2) Receptor Heteromerization and Its Psychoactive Behavioral Function. Journal of Biological Chemistry, 2012, 287, 44301-44319.	3.4	122
77	Regulation of munc18-1 and syntaxin-1A interactive partners in schizophrenia prefrontal cortex: down-regulation of munc18-1a isoform and 75 kDa SNARE complex after antipsychotic treatment. International Journal of Neuropsychopharmacology, 2012, 15, 573-588.	2.1	28
78	HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nature Neuroscience, 2012, 15, 1245-1254.	14.8	247
79	A combined analysis of microarray gene expression studies of the human prefrontal cortex identifies genes implicated in schizophrenia. Journal of Psychiatric Research, 2012, 46, 1464-1474.	3.1	68
80	Differential regulation of RGS proteins in the prefrontal cortex of short- and long-term human opiate abusers. Neuropharmacology, 2012, 62, 1044-1051.	4.1	10
81	Long lasting effects of early-life stress on glutamatergic/GABAergic circuitry in the rat hippocampus. Neuropharmacology, 2012, 62, 1944-1953.	4.1	103
82	Regulation of central noradrenergic activity by 5-HT3 receptors located in the locus coeruleus of the rat. Neuropharmacology, 2012, 62, 2472-2479.	4.1	21
83	The function of alpha-2-adrenoceptors in the rat locus coeruleus is preserved in the chronic constriction injury model of neuropathic pain. Psychopharmacology, 2012, 221, 53-65.	3.1	40
84	Levels of Gsα(short and long), Gαolf and Gβ(common) subunits, and calcium-sensitive adenylyl cyclase isoforms (1, 5/6, 8) in post-mortem human brain caudate and cortical membranes: Comparison with rat brain membranes and potential stoichiometric relationships. Neurochemistry International, 2011, 58, 180-189.	3.8	2
85	G _i protein coupling to adenosine A ₁ –A _{2A} receptor heteromers in human brain caudate nucleus. Journal of Neurochemistry, 2010, 114, 972-980.	3.9	14
86	α2-Adrenoceptor Functionality in Postmortem Frontal Cortex of Depressed Suicide Victims. Biological Psychiatry, 2010, 68, 869-872.	1.3	40
87	Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. Neurochemistry International, 2010, 56, 829-833.	3.8	49
88	Characterization of regulators of G-protein signaling RGS4 and RGS10 proteins in the postmortem human brain. Neurochemistry International, 2010, 57, 722-729.	3.8	10
89	Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: Antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. European Neuropsychopharmacology, 2010, 20, 721-730.	0.7	28
90	In vivo potentiation of reboxetine and citalopram effect on extracellular noradrenaline in rat brain by α2-adrenoceptor antagonism. European Neuropsychopharmacology, 2010, 20, 813-822.	0.7	30

J JAVIER MEANA

#	Article	IF	CITATIONS
91	Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology, 2009, 206, 313-324.	3.1	108
92	Guanidine and 2-Aminoimidazoline Aromatic Derivatives as α ₂ -Adrenoceptor Ligands: Searching for Structureâ"Activity Relationships. Journal of Medicinal Chemistry, 2009, 52, 601-609.	6.4	36
93	Novel synthesis and pharmacological evaluation as α2-adrenoceptor ligands of O-phenylisouronium salts. Bioorganic and Medicinal Chemistry, 2008, 16, 8210-8217.	3.0	14
94	Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97.	27.8	739
95	Human adenosine deaminase as an allosteric modulator of human A ₁ adenosine receptor: abolishment of negative cooperativity for [³ H](R)â€pia binding to the caudate nucleus. Journal of Neurochemistry, 2008, 107, 161-170.	3.9	45
96	Guanidine and 2-Aminoimidazoline Aromatic Derivatives as α ₂ -Adrenoceptor Antagonists. 2. Exploring Alkyl Linkers for New Antidepressants. Journal of Medicinal Chemistry, 2008, 51, 3304-3312.	6.4	39
97	Monoamine oxidase B activity is increased in human gliomas. Neurochemistry International, 2008, 52, 230-234.	3.8	20
98	Specific binding of [3H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death. European Neuropsychopharmacology, 2008, 18, 55-61.	0.7	2
99	El sistema noradrenérgico en la neurobiologÃa de la depresión. Psiquiatria Biologica, 2008, 15, 162-174.	0.1	0
100	Guanidine and 2-Aminoimidazoline Aromatic Derivatives as α ₂ -Adrenoceptor Antagonists, 1: Toward New Antidepressants with Heteroatomic Linkers. Journal of Medicinal Chemistry, 2007, 50, 4516-4527.	6.4	39
101	On the search of new I2-IBS aliphatic ligands: Bis-guanidino carbonyl derivatives. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6009-6012.	2.2	2
102	Levels of G-protein αq/11 subunits and of phospholipase C-β(1–4), -γ, and -δ1 isoforms in postmortem human brain caudate and cortical membranes: Potential functional implications. Neurochemistry International, 2006, 49, 72-79.	3.8	7
103	Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the μ-opioid receptor and I2–imidazoline binding sites. Bioorganic and Medicinal Chemistry, 2006, 14, 6570-6580.	3.0	45
104	The N251K functional polymorphism in the α2A-adrenoceptor gene is not associated with depression: a study in suicide completers. Psychopharmacology, 2006, 184, 82-86.	3.1	11
105	Heterotrimeric G Proteins: Insights into the Neurobiology of Mood Disorders. Current Neuropharmacology, 2006, 4, 127-138.	2.9	28
106	Characterization of noradrenaline release in the locus coeruleus of freely moving awake rats by in vivo microdialysis. Psychopharmacology, 2005, 180, 570-579.	3.1	39
107	Evaluation of a pharmacology educational activity based on a research project: a randomized, controlled and blind analysis of medical students' perceptions. Medical Teacher, 2005, 27, 53-60.	1.8	6
108	Opposite changes in Imidazoline 12 receptors and α2-adrenoceptors density in rat frontal cortex after induced gliosis. Life Sciences, 2005, 78, 205-209.	4.3	7

#	Article	IF	CITATIONS
109	Differential Postmortem Delay Effect on Agonist-Mediated Phospholipase Cβ Activity in Human Cortical Crude and Synaptosomal Brain Membranes. Neurochemical Research, 2004, 29, 1461-1465.	3.3	8
110	Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for μ-opioid receptors and I2-imidazoline binding sites. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 491-493.	2.2	20
111	Characterization of [3 H]idazoxan binding sites on human platelets. Platelets, 2002, 13, 241-246.	2.3	19
112	Distribution of prolyl endopeptidase activities in rat and human brain. Neurochemistry International, 2002, 40, 337-345.	3.8	72
113	In vivo tonic modulation of the noradrenaline release in the rat cortex by locus coeruleus somatodendritic α2-adrenoceptors. European Journal of Pharmacology, 2002, 442, 225-229.	3.5	45
114	Effects of Age, Postmortem Delay and Storage Time on Receptor-mediated Activation of G-proteins in Human Brain. Neuropsychopharmacology, 2002, 26, 468-478.	5.4	42
115	Long-Acting Fentanyl Analogues: Synthesis and Pharmacology of N-(1-Phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidyl)propanamides. Bioorganic and Medicinal Chemistry, 2002, 10, 817-827.	3.0	35
116	Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for μ opioid and I2-imidazoline receptors: synthesis and pharmacological screening. Bioorganic and Medicinal Chemistry, 2002, 10, 1009-1018.	3.0	29
117	I 2 -Imidazoline Binding Site Affinity of a Structurally Different Type of Ligands. Bioorganic and Medicinal Chemistry, 2002, 10, 1525-1533.	3.0	20
118	Assessment of the Quality of Medical Documents Issued in Central Police Stations in Madrid, Spain: The Doctor's Role in the Prevention of III-Treatment. Journal of Forensic Sciences, 2002, 47, 293-298.	1.6	8
119	Assessment of the quality of medical documents issued in central police stations in Madrid, Spain: the doctor's role in the prevention of ill-treatment. Journal of Forensic Sciences, 2002, 47, 293-8.	1.6	3
120	Regulation of phospholipase Cβ activity by muscarinic acetylcholine and 5-HT2 receptors in crude and synaptosomal membranes from human cerebral cortex. Neuropharmacology, 2001, 40, 686-695.	4.1	25
121	I2-Imidazoline Receptors in Platelets of Patients with Parkinson's Disease and Alzheimer's Type Dementiaa. Annals of the New York Academy of Sciences, 1999, 881, 199-202.	3.8	6
122	Densities of I2-Imidazoline Receptors, Imidazoline Receptor Proteins, and MAO-B Sites in Human Gliomas and Pituitary Adenomasa. Annals of the New York Academy of Sciences, 1999, 881, 203-207.	3.8	2
123	Differential modulation of α2-adrenoceptor subtypes in rat kidney by chronic desipramine treatment. Life Sciences, 1999, 64, 2327-2339.	4.3	3
124	Selective Increase of α _{2A} â€Adrenoceptor Agonist Binding Sites in Brains of Depressed Suicide Victims. Journal of Neurochemistry, 1998, 70, 1114-1123.	3.9	118
125	Somatodendritic α ₂ â€Adrenoceptors in the Locus Coeruleus Are Involved in the In Vivo Modulation of Cortical Noradrenaline Release by the Antidepressant Desipramine. Journal of Neurochemistry, 1998, 71, 790-798.	3.9	97
126	Differences in Criminal Activity Between Heroin Abusers and Subjects Without Psychiatric Disorders—Analysis of 578 Detainees in Bilbao, Spain. Journal of Forensic Sciences, 1998, 43, 993-999.	1.6	17

#	Article	IF	CITATIONS
127	The Density of Monoamine Oxidase B Sites Is Not Altered in the Postmortem Brain of Alcoholics. Alcoholism: Clinical and Experimental Research, 1997, 21, 1479-1483.	2.4	4
128	Modulation of catecholamine release by α2-adrenoceptors and I1-imidazoline receptors in rat brain. Brain Research, 1997, 744, 216-226.	2.2	38
129	α2-Adrenoceptor subtypes in the human brain: a pharmacological delineation of [3H]RX-821002 binding to membranes and tissue sections. European Journal of Pharmacology, 1996, 310, 83-93.	3.5	48
130	Increased density of I2-imidazoline receptors in human glioblastomas. NeuroReport, 1996, 7, 1393-1396.	1.2	31
131	Increased density of μ-opioid receptors in the postmortem brain of suicide victims. Brain Research, 1995, 682, 245-250.	2.2	124
132	I2-Imidazoline Receptors in the Healthy and Pathologic Human Brain. Annals of the New York Academy of Sciences, 1995, 763, 178-193.	3.8	10
133	Prevalence of sexual torture in political dissidents. Lancet, The, 1995, 345, 1307.	13.7	5
134	μ-Opioid receptor and α2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts. Psychopharmacology, 1994, 115, 135-140.	3.1	71
135	Autoradiographic Demonstration of Increased α ₂ â€Adrenoceptor Agonist Binding Sites in the Hippocampus and Frontal Cortex of Depressed Suicide Victims. Journal of Neurochemistry, 1994, 63, 256-265.	3.9	85
136	Evidence of increased non-adrenoceptor [3H]idazoxan binding sites in the frontal cortex of depressed suicide victims. Biological Psychiatry, 1993, 34, 498-501.	1.3	42
137	Cholecystokinin is released from a crossed corticostriatal pathway. NeuroReport, 1992, 3, 905-908.	1.2	24
138	α2-Adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biological Psychiatry, 1992, 31, 471-490.	1.3	160
139	Decreased Density of Presynaptic ?2-Adrenoceptors in Postmortem Brains of Patients with Alzheimer's Disease. Journal of Neurochemistry, 1992, 58, 1896-1904.	3.9	44
140	Acute ethanol intoxication may not alter α2-adrenoceptors in the human brain. Psychopharmacology, 1992, 107, 132-134.	3.1	3
141	Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims. Psychopharmacology, 1992, 109, 410-414.	3.1	21
142	Characterization and Regional Distribution of ?2-Adrenoceptors in Postmortem Human Brain Using the Full Agonist [3H]UK 14304. Journal of Neurochemistry, 1989, 52, 1210-1217.	3.9	44